"We remain highly focused on, and are progressing, the key commercial goal to secure one or more therapeutic out-licencing transactions"
#ROQ#Cancer#mRNA
"We remain highly focused on, and are progressing, the key commercial goal to secure one or more therapeutic out-licencing transactions."
CEO Ajan Reginald
Read more here: proactiveinvestors.co.uk/companies/news…#ROQ#Cancer#RNA
The significant pre-clinical development achievements have put the Company in a position to open various out licencing discussions with big pharma as well as a private equity fund across the US, EU and Japan, where talks are ongoing
#ROQ#Cancer#mRNA
The mRNA cancer market is a highly attractive new field of medicine (~$31 billions) and is led by Pfizer, Moderna and BioNTech.
Roquefort Therapeutics is well positioned in this field, with four mRNA sequences that uniquely target Midkine.
#ROQ#Cancer#mRNA
Our portfolio of five potential first-in-class medicines includes:
Newly validated targets STAT-6
Midkine
Novel modalities siRNA,
mRNA and
Cell therapy
We are well positioned to create significant shareholder value in this market
#ROQ#Cancer#mRNA
"The MK cell program has demonstrated both direct killing and natural killer cell activation in a commercially attractive field which has significant interest from large pharmaceutical companies."
Roquefort Therapeutics CEO Ajan Reginald
#ROQ#Cancer#mRNA#siRNA
" Successfully combining our Midkine mRNA with LNP delivery creates potential for a highly promising new medicine for liver cancer and the novel STAT-6 siRNAs have shown great promise in colon cancer."
#ROQ#Cancer#mRNA
📅 On 13 March and 14 March our CEO Ajan Reginald will be participating at the RNA Leaders Europe Congress in Basel, Switzerland
👉 Ajan will be the moderator at the keynote plenary “Investing in RNA – Nucleic Acid Targets, Vaccines & Therapeutics”
linkedin.com/posts/roquefor…
"We remain in active out licencing discussions with Big Pharma companies and a specialist private equity fund across the US, EU and Japan and will update the market should a binding agreement be entered into with one or more partners."
#ROQ#Cancer#mRNA
Our CEO @AjanReginald will be in Basel next week part of the keynote panel on investing in RNA medicines and to meet representatives from Big Pharma
#ROQ#Cancer#mRNA
"The Company remains in discussions with multiple potential partners and looks forward to updating shareholders as to our progress in due course."
Roquefort Therapeutics CEO, Ajan Reginald
#ROQ#Cancer#mRNA#siRNA
"Our portfolio is attracting interest from Big Pharma and private equity, and in line with our strategy, we are engaged in discussions with these potential partners."
#ROQ#Cancer#mRNA#siRNA
We are developing first in class medicines.
The Company remains in discussions with multiple potential partners and looks forward to updating shareholders as to our progress in due course.
#ROQ#Cancer#mRNA
Our CEO @AjanReginald will take part in a panel discussion at the Capital Markets & Deal-Making 2024 Expectations: A Beaming Horizon of Opportunity, Innovation, Investments, and Partnerships; Tuesday 20th Feb.
lsxleaders.com/capital-market…#ROQ#Cancer#mRNA
The mRNA cancer market is a highly attractive new field of medicine (~$31 billions) and is led by Pfizer, Moderna and BioNTech.
Roquefort Therapeutics is well positioned in this field, with four mRNA sequences that uniquely target Midkine.
#ROQ#Cancer#mRNA
The Midkine RNA oligonucleotide & STAT-6 siRNA programs have been undergoing studies in combination with proprietary lipid nanoparticle delivery systems
The initial studies have shown successful encapsulation with the LNPs & biological activity of the combination in liver cancer
6K Followers 1K FollowingBiotech Entrepreneur & CEO @RoquefortTherap @Celixirltd. ExBCG, Roche & Novacyt. Fulbright Scholar, Uni of Oxford & Harvard Business School. Personal opinions
4K Followers 926 FollowingTrades/invests in small caps. Tries to adapt to the macro picture. Focusing on oil and gas/commodities as they are enjoying strong pricing. Looking for value.
30K Followers 3K FollowingWe lead the world in up-to-the-minute, multi-media news provision.
We receive compensation for publishing content here on behalf of our clients. T&Cs apply
2K Followers 411 FollowingInvestor,entrepreneur, trader with some great successes from managing risk and not getting greedy! Every day is an opportunity to learn and grow!
314 Followers 1K FollowingDSI is a full service CMC Drug Development Consulting Firm, assisting emerging Biotech and Pharma sponsors with CMC, Regulatory and QA for NCEs & Biologics
94 Followers 629 Followingالعالمة الفلكية والمعالجة الروحانية ام سلمان لعلاج المس والعين والحسد وفك السحر وجلب الحبيب العنيد رغما عنه
معرفة مكان السحر ومن وضعه
وقلب السحر على الساحر
6K Followers 1K FollowingBiotech Entrepreneur & CEO @RoquefortTherap @Celixirltd. ExBCG, Roche & Novacyt. Fulbright Scholar, Uni of Oxford & Harvard Business School. Personal opinions
20K Followers 367 FollowingFormer micro-cap equity analyst, former micro-cap-focussed investment manager.
Now managing my own book, predominantly trading UK micro-caps.
https://t.co/MkxqFCacIR
14K Followers 612 FollowingFull Time AIM Investor..O you who believe! Do not squander one another’s wealth in vanities, but let there be amongst you traffic and trade by mutual good will.
23K Followers 98 Following@Share_Talk official Twitter account https://t.co/dr4HNUXWRh The digital stock market - news platform with the #UK highest engagement figures across #socialmedia
18K Followers 922 FollowingNOEL. Momentum Trader, providing guidance and mentorship in chart analysis. My approach is firmly rooted in Price Action principles.
6K Followers 529 FollowingFull time Investor/trader. Research hard, stay disciplined and keep learning. Always DYOR ! PROTECT CAPITAL - Professional lover of life 🚴😎
30K Followers 3K FollowingWe lead the world in up-to-the-minute, multi-media news provision.
We receive compensation for publishing content here on behalf of our clients. T&Cs apply
5K Followers 67 FollowingPaul Hill: Investor, capital markets commentator & analyst. All views are my own. Please DYOR. Full disclosure available on https://t.co/3JUBBuJbNy
14K Followers 1K FollowingUK Based Equities Trader. Former Soldier British Army,Served in 1st Gulf War at 18 years old,NI & then BP, DS, UC. Covert Ops,Surveillance .💥
3K Followers 3K FollowingInvestor/Trader, mainly on AIM market. BUY low sell HIGH, dont let anyone dictate to you where your hard earned money is invested/traded. Be your own boss.
4K Followers 4K FollowingEnhance your competitive presence through research, message creation, social execution leading towards demonstrated revenue growth!
932 Followers 642 FollowingWe are AIM brokers and advisers dedicated to fund raising, share price support and providing market-driven corporate finance advice. https://t.co/egMOb1qtHj
6K Followers 88 FollowingA leading independent financial services firm with operations in North America, UK & Europe, Asia and Australia. Also see @CGWM_CA and @CGWM_UK
2K Followers 82 FollowingAn independent monthly newsletter alerting you to outstanding opportunities in lesser-known growth stocks. Our Tweets do not constitute investment advice.
2K Followers 256 FollowingMello is an open community of serious and high net worth private investors. We run investor events which bring together investors and quality listed companies.
2K Followers 508 FollowingLive, interactive presentations, with management from UK listed companies that matter to you, regardless of the number of shares you own, or where you live.
32K Followers 3K FollowingScience at The Times - Tweets in personal capacity. My book: about boffins, derring do and the radio war https://t.co/za2mmy25r5
7K Followers 1K FollowingScience Correspondent for the Guardian. Book lover, archer and stitcher. Shortlisted for British Science Journalist of the Year 2021.
46K Followers 1K FollowingGuardian science editor and podcast presenter | PhD | Massive, shortlisted Royal Society Science Book Prize | Sony Award | Leaks to [email protected]
753 Followers 1K FollowingSenior Content Writer at Unbiased, Consumer Champion of the Year at #PFSAwards and finalist @Headlinemoney_
Enjoys baking, TV, good books & video games.
9K Followers 0 FollowingResearch Director at DT Consulting, an Indegene company. Focus on customer experience (CX) and digital transformation in pharma https://t.co/AgpZ2k9PE8
80 Followers 37 FollowingFounder of leading #pharma trade magazine PharmaTimes. Interested in all things healthcare, Irish rugby, John McCormick and voices raised in song.
2K Followers 2K FollowingManaging editor Europe, commercial @PharmaScrip. Interested in #pharma #health #MUFC and old guys who can't sing #Dylan #Cohen